Biomarker Technologies has announced the launch of a new clinical trial to evaluate a revolutionary blood test that may change the way we detect breast cancer. In previous clinical trials this test was shown to be very effective in detecting breast cancer. It's accuracy in detecting breast cancer was shown to be significantly higher than that of mammograms.
This new method of breast cancer detection is based on evaluation of blood for various cancer related biomarkers. These biomarkers are specific proteins having concentrations that are measurably different in patients with breast cancer. The BT Test is a first-of-its-kind blood diagnostic that detects the presence of breast cancer at the molecular level.
Researchers are planning to enroll 430 women referred for biopsy and 125 women referred for other types of cancer, and 300 healthy subjects into the study. Investigators expect that be study will be completed in four months. Collection of blood samples is expected to begin during the early part of March 2006.
"This clinical study will move the BT Test forward in its FDA approval as first a supplementary and then a stand-alone screening tool for early breast cancer detection," said William Gartner, CEO and President of Biomarker Technologies. "With fewer false negative and false positive diagnoses, this cost-effective blood test may not only offer vastly superior early-detection capabilities in routine examinations, but may also help patients avoid unnecessary needle biopsies." |
